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Protein trans-splicing based dual-vector factor VIII (FVIII) gene delivery is adversely affected by less efficiency of protein 
splicing. We sought to increase the amount of spliced FVIII protein and plasma coagulation activity in dual-vector FVIII 
transgene in mice by means of strengthening the interaction of inteins, protein splicing elements, thereby facilitating protein 
trans-splicing. Dual-vector delivery of the FVIII gene in cultured cells showed that replacement of Met226 in the heavy chain 
and Asp1828 in the light chain with Cys residues could facilitate inter-chain disulfide linking and improve protein 
trans-splicing, increasing the levels of spliced FVIII protein. In this study, C57BL/6 mice were coadministered dual vectors of 
intein-fused human FVIII heavy chain and light chain with Cys mutations via portal vein injection into the liver. Forty-eight 
hours post-injection, plasma was collected and analyzed for FVIII antigen concentration and coagulation activity. These mice 
showed increased circulating FVIII heavy chain polypeptide (442±151 ng mL1 vs. 305±103 ng mL1) and coagulation activi-
ty (1.46±0.37 IU mL1 vs. 0.85±0.23 IU mL1) compared with control mice co-administered dual vectors expressing the heavy 
and light chains of wild-type FVIII. Moreover, coagulation activity was similar to that of mice receiving a single vector ex-
pressing FVIII (1.79±0.59 IU mL1). These findings indicate that improving protein trans-splicing by inter-chain disulfide 
bonding is a promising approach for increasing the efficacy of dual-vector based FVIII gene transfer. 
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Protein trans-splicing based dual-vector cotransfer of FVIII 
heavy and light chain genes is effective in overcoming the 
capacity limit of adeno-associate virus (AAV) vectors. This 
strategy uses split intein, a protein splicing element, linked 
to the FVIII heavy and light chains, resulting in functionally 
peptide-joined intact FVIII protein, with intein fragments 
removed post-translationally [1]. As an inter-peptide trans- 
splicing reaction, its efficiency depends on the strength of 
the molecular interactions, although splicing information 
located in the intein molecules and protein splicing occur 
spontaneously without any auxiliary factors or energy con-
sumption [2]. In our recent study, in which the FVIII gene 
was transfected into cultured cells using the dual-vector, the 
spliced FVIII protein, with coagulation activity recovered, 
was observed, but these cells contained unspliced precursors 
of intein fused heavy and light chain polypeptides [1]. The-
se nonfunctionally unspliced protein precursors may be 
immunogenic. The amount of spliced FVIII protein depends 
on its splicing efficiency; this, in turn, determines the coag-
ulation activity and the efficacy of gene therapy. Another 
dual-vector gene delivery strategy based on intracellular 
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formation of heterodimeric FVIII causes obvious chain im-
balance because of inefficient heavy chain secretion, which 
reduces efficacy of transgene and may also destabilize host 
cells, with excessive retention of intracellular heavy chain 
polypeptide even inducing apoptosis [3,4].  
Protein splicing reactions are not dependent on any cel-
lular mechanisms, with an ability of protein splicing intra-
cellularlly before secretion and extracellularlly after secre-
tion of heavy and light chains to produce intact FVIII pro-
tein. Moreover, peptide bonded light chain to heavy chain 
shows a cis promotive effect on secretion of heavy chain [1]. 
Improved protein trans-splicing between two peptides, in 
protein splicing based dual-vector FVIII gene delivery, may 
increase the amount of spliced FVIII protein and procoagu-
lant activity, thus enhancing the results of gene therapy. 
Using cultured cells, we recently demonstrated that an inter- 
chain disulfide bond between B domain-deleted FVIII 
(BDD-FVIII) heavy and light chains can increase the 
amount of protein-spliced BDD-FVIII protein and its coag-
ulation activity [5]. We have expanded these findings to a 
mouse model, by injecting two vectors, one each encoding 
the BDD-FVIII heavy and light chain, into the portal vein of 
mice, suggesting a strategy of gene therapy for patients with 
hemophilia A.  
1  Materials and methods 
1.1  Materials  
The plasmid vector pCMV-F8 expressing human BDD- 
FVIII, pCMV-HCIntN and pCMV-IntCLC with Ssp DnaB 
intein-fused BDD-FVIII heavy and light chain genes have 
been described previously [1]. C57BL/6 mice were pur-
chased from Vital River Laboratories (VRL, Beijing, 
China).  
Pfu, a high fidelity DNA polymerase was obtained from 
Stratagene (Santa Clara, CA, USA), the DNA ligase kit 
from New England Biolabs (Ipswich, MA, USA), and the 
HiSpeed Plasmid Midi Kit from Qiagen (Dusseldorf, 
Germany).  
Recombinant human factor VIII protein was obtained 
from BioChain (Hayward, CA, USA). Monoclonal antibod-
ies against FVIII heavy and light chain, ESH5 and ESH8 
were purchased from American Diagnostica (Greenwich, 
CT, USA). Horseradish peroxidase (HRP) conjugated rabbit 
anti-human FVIII polyclonal antibody was purchased from 
Novus (Littleton, CO, USA). Normal pooled human refer-
ence plasma and FVIII deficient plasma were obtained from 
George King Biomedical (Overland Park, KS, USA). A 
chromogenic FVIII coagulation activity assay kit was pur-
chased from Chromogenix (Milan, Italy). 
1.2  Vector construction 
Inverse PCR was used to introduce the Met662Cys and 
Asp1828Cys mutations into the heavy and light chains of 
BDD-FVIII. DNA fragments were generated using the 
plasmids pCMV-HCIntN and pCMV-IntCLC as templates 
and the pairs of primers 5′-TGTGTCTATGAAGACAC- 
ACTCACC-3′ (forward) and 5′-TTTGTGTTTGAAGGT- 
ATATCCAG-3′ (reverse) for heavy chain, and 5′-TGTG- 
AGTTTGACTGCAAAGCCTG-3′ (forward) and 5′-TTTA- 
GTGGGTGCCATATGATG-3′ (reverse) for light chain, 
respectively. The resulting DNAs were self-ligated using T4 
DNA ligase, leading to the formation of the two circular 
plasmids, pCMV-SHCIntN and pCMV-IntCSLC.  
1.3  Animal procedures 
Normal C57BL/6 mice were injected via the portal vein 
with 200 μg each of the column-purified plasmids, 
pCMV-SHCIntN and pCMV-IntCSLC, in 2 mL of saline as 
previously described [6]. As controls, 200 μg of both 
pCMV-HCIntN and pCMV-IntCLC, the single vector 
pCMV-F8 for BDD-FVIII, were administered (n=6 per 
group). After 48 h, blood samples were collected by tail clip 
using sodium citrate as an anticoagulant at a final concen-
tration of 0.38% (w/v). The blood samples were centrifuged 
for 10 min at 2000×g at 4°C, and the plasma was aliquoted 
and used for FVIII assays.  
1.4  Plasma FVIII antigen assay  
Plasma concentrations of BDD-FVIII HC and LC antigens 
were measured using chain-specific ELISAs as previously 
described [7]. Human recombinant FVIII protein was used 
as the standard and serially diluted in blocking buffer     
to concentrations of 320 to 10 ng mL1. Ninety-six well 
ELISA plates were coated with 2 g mL1 of monoclonal 
antibody to human FVIII heavy chain (ESH5; heavy chain- 
specific ELISA) or light chain (ESH8; light chain-specific 
ELISA) overnight at 4°C, washed, and incubated with 
blocking buffer for 2 h at 37°C. After washing, 100 μL di-
luted standards and plasma samples were added to each well, 
and the plates were incubated at 37°C for 1 h. The plates 
were washed, 100 μL of HRP-conjugated rabbit anti-human 
FVIII polyclonal antibody (2 μg mL1) were added to each 
well, and the plates were again incubated for 1 h at 37°C. 
After a final washing, antigen was detected by incubating 
with the substrate OPD for 30 min at 37°C. The reactions 
were stopped by adding 2 mol L1 of H2SO4, and the plates 
were read at a wavelength of 490 nm. Standard curves were 
plotted from the diluted standards, and the concentrations of 
human HC and LC in plasma samples produced by the 
transgenes were deduced from the standard curves. 
1.5  Plasma FVIII coagulation activity assay  
Coatest chromogenic assays were used to measure trans- 
gene produced human FVIII coagulation activity in mouse 
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plasma as described with some modifications [6]. Total 
plasma FVIII activity consists of both mouse and transgene 
generated human FVIII activities. Normal pooled human 
plasma was used as a standard and defined as 1 mL of this 
plasma containing one unit FVIII activity (IU mL1) and 
200 ng FVIII protein (ng mL1). This standard was serially 
diluted with FVIII-deficient human plasma, such that FVIII 
activity ranged from 1 (undiluted) to 0.0313 IU mL1. 10 μL 
of each standard or mouse plasma diluted into FVIII-   
deficient plasma were incubated at 37°C for 15 min in the 
presence or absence of 2 μL of the anti-human FVIII 
light-chain antibody ESH8 (1 mg mL1) and immediately 
placed on ice to deplete human FVIII activity. After serial 
reactions according to kit instructions, plates were read at 
405 nm and standard curves were plotted based on the dif-
ference in absorbance of standard samples incubated in the 
presence or absence of ESH8 versus corresponding FVIII 
activity. The absorbance of plasma samples was also meas-
ured at 405 nm and FVIII activity was obtained from stand-
ard curves. The difference in FVIII activity between 
ESH8-untreated and ESH8-treated samples represents hu-
man FVIII activity. 
1.6  Statistical analysis  
All results are presented as mean±SD and compared us-
ing two-tailed Student’s t-tests, with P<0.05 considered 
statistically significant. 
2  Results 
2.1  Structures of BDD-FVIII and its intein fused 
heavy and light chains  
The full length human FVIII molecule consists of 2351 
amino acid (aa) residues with a 19-aa N-terminal signal 
peptide sequence and a domain arrangement from the N- to  
the C-terminus of A1-A2-B-A3-C1-C2. A functional, 
smaller version of FVIII, B-domain-deleted FVIII (BDD- 
FVIII), results from the removal of most of the centrally 
located B domain from Ile761 to Asn1639. Cleavage of 
BDD-FVIII before Ser1657 generates separate heavy (HC) 
and light (LC) chains. The N-part of Ssp DnaB intein (IntN) 
was added to the C-terminus of HC and the C-part of Ssp 
DnaB intein (IntC), preceded by the signal sequence (SS) of 
FVIII, was added to the N-terminus of LC. These steps 
yielded HCIntN and IntCLC, respectively. The residues in 
HCIntN and IntCLC corresponding to the Met662 and 
Asp1828 residues of the FVIII were each mutated to Cys, 
generating SHCIntN and IntCSLC (Figure 1).  
2.2  Transgenes produced plasma concentrations of 
BDD-FVIII light and heavy chains  
We found that injection of the BDD-FVIII light chain vec- 
tor alone had no effect on the plasma concentration of 
BDD-FVIII light chain (Figure 2). When heavy and light 
chain genes were coinjected into mice, the plasma light 
chain concentrations in the absence and presence of the Cys 
mutation were 827±197 and 897±208 ng mL1, respectively 
(P>0.05). Moreover, light chain concentrations were similar 
in mice administered the light chain gene alone. The light 
chain detected in plasma has three sources: light chain in 
intracellularlly protein trans-splicing produced and secreted 
BDD-FVIII, light chain in post-secretion spliced BDD- 
FVIII, and directly secreted non-spliced light chain precur-
sor. Our findings therefore suggest that secretion of light 
chain is independent of inter-chain disulfide linking. The 
single vector BDD-FVIII transgene had a mean plasma light 
chain concentration of 521±112 ng mL1, all bound quanti-
tatively to heavy chain as secreted heterodimeric BDD- 
FVIII. The reduced amount of secreted light chain in single- 
than in dual-vector BDD-FVIII transgene may be due to the 
binding of heavy chain to the ER chaperone protein BiP,  
 
 
Figure 1  Schematic representation of BDD-FVIII and the intein-fused heavy and light chains. BDD-FVIII was generated from FVIII by deleting most of 
its B-domain. BDD-FVIII was split into heavy chain (HC) and light chain (LC), and these were fused with the N- and C-parts of Ssp DnaB intein (IntN, 
IntC), respectively, generating HCIntN and IntCLC. Site-directed mutagenesis was used to insert Cys mutations into Met662 of HC in HCIntN and Asp1828 of 
LC in IntCLC, resulting in SHCIntN and IntCSLC. SS, signal sequence of FVIII. 
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which hindered the secretion of light chain resulting in a 
lower plasma concentration [8]. 
Chain-specific ELISA was used to determine the plasma 
concentration of heavy chain generated by transgene (Fig-
ure 3). Plasma heavy chain concentration was very low in 
mice injected with intein-fused heavy chain gene alone, 
whether wild-type or Cys mutated, but was significantly 
higher in mice injected with dual-vector encoding Cys mu-
tated than wild-type heavy and light chains (442±151 ng 
mL1 vs. 305±103 ng mL1, P<0.05). The secreted heavy 
chain includes intracellularly spliced and secreted and 
post-secretion spliced BDD-FVIII, as well as unspliced in-
tein-fused heavy chain precursor. These findings demon-
strate that linking via an inter-chain disulfide bond im-
proves protein trans-splicing, resulting in more spliced 
BDD-FVIII and more heavy chain secreted with light chain 
under cis-promotion of light chain. The increase in secre-
tion of light and heavy chains resulted in an increase in het-
erodimeric BDD-FVIII, as shown by the increase in coagu-
lation activity. Moreover, increased secretion of heavy 
chain reduced its cellular retention and resultant chain im-
balance and enhanced cell stability [4]. The plasma concen-
tration of heavy chain secreted by single vector BDD-FVIII 
transgene was 478±125 ng mL1, similar to the concentra-
tion of light chain.  
2.3  Dual-vector transgene generated plasma coagula-
tion activity  
The coagulation activity of plasma resulting from injection 
of transgene was determined by chromogenic analysis (Fig-
ure 4). The FVIII coagulation activity in plasma of mice 
co-injected with intein-fused and Cys mutated BDD-FVIII 
heavy and light chain genes was significantly higher than 
that of intein-fused, wild-type BDD-FVIII heavy and light 
chain genes (1.46±0.37 IU mL1 vs. 0.85±0.23 IU mL1, 
P<0.05), indicating that the inter-chain disulfide linkage 
between the two mutated Cys residues enhanced the inter-
action of the two chains. Thus, inter-molecular trans-  
splicing was similar to intra-molecular cis-splicing in pro-
ducing more spliced BDD-FVIII protein. A cis-prompting  
 
 
Figure 2  Concentration of light chain in plasma. 
 
Figure 3  Concentration of heavy chain in plasma. 
 
Figure 4  Coagulation activity of plasma. 
effect of light chain on heavy chain secretion increased se-
cretion of heterodimeric BDD-FVIII into plasma, resulting 
in elevated coagulation activity. Injection of single vector 
BDD-FVIII gene generated a plasma coagulation activity of 
1.79±0.59 IU mL1, similar to that of dual-vector Cys mu-
tant BDD-FVIII transgene, indicating that dual-vector de-
livery of BDD-FVIII was as effective as a single vector de-
livery of the BDD-FVIII transgene.   
Although all heavy and light chains in BDD-FVIII pro-
tein expressed from single vector transgene contributed to 
coagulation activity (100%), this was not necessarily true 
for the dual vector strategy. We therefore calculated the 
ratios of heavy and light chain involved in plasma coagula-
tion activity in the plasma of dual-vector BDD-FVIII gene 
injected mice (Table 1). We found that injection of in-
tein-fused and Cys mutated heavy and light chain genes 
increased the contribution of both chains to plasma coagula-
tion activity relative to the co-delivery of wild-type 
BDD-FVIII. Increased secretion of heavy chain as spliced 
FVIII effectively decreased the amount of unmatched free 
light chain.  
3  Discussion 
Gene therapy is considered promising for the treatment of 
patients with hemophilia A and may replace transfusion 
therapy with plasma derived or recombinant FVIII protein. 
These therapies are costly, generate inhibitory antibodies 
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Table 1  Contribution of HC and LC produced by transgenes to plasma coagulation activity 
Group Percent functionally active HC Percent functionally active LC 
BDD-FVIII 100 100 
SHCIntN+IntCSLC 88.2 47.4 
HCIntN+IntCLC 74.4 29.9 
 
and promote the spread of infectious diseases. Effective 
gene therapy depends on the duration of therapeutic levels 
of plasma coagulation activity. AAV vectors have been 
considered ideal gene carriers for hemophilia A gene thera-
py because of their ability to maintain sustained and stable 
expression of coagulation factors in targeted liver and skel-
etal muscle tissues [911]. However, the 4.7 kb packaging 
capacity of AAV vectors has limited their use in the 
transport of the large FVIII gene. Moreover, although the 
functional miniature BDD-FVIII cDNA is only 4.5 kb long, 
it exceeds the maximum capacity of AAV vectors after the 
addition of sequences of gene expression regulatory ele-
ments. Newly synthesized, intracellular FVIII protein is a 
single-chain polypeptide, 200 kD in size. Post-translational 
processing results in a heterodimer composed of a heavy 
and a light chain, and the secreted protein binds to von Wil-
lebrand factor (vWF) [12]. An alternative strategy, which 
overcomes the limited capacity of AAV vectors and was 
based on the understanding of intracellular FVIII processing, 
uses two AAV vectors to co-transfer FVIII heavy and light 
chain genes [13]. However, the primary disadvantage of this 
approach was the inefficient heavy chain secretion, which 
was ~1–2 logs less than that of light chain [3,6]. Secretion 
of excess light chain as a non-matched monomer may in-
duce an immune response in the host [3,6]. Because hetero-
dimers of heavy and light chains only form intracellularly, it 
is necessary to transfect two vectors encoding both chains 
into the same target cells [14]. However, transfection of an 
increased dose of vector encoding heavy chain had little 
effect on its secretion [7]. Mutations in BDD-FVIII, such as 
the Phe309Ser mutation in the heavy chain, and modifica-
tions, such the addition of up to six glycosylation sites to the 
B domain, were found to increase BDD-FVIII secretion by 
almost 20-fold [15,16]. However, transfection of modified 
heavy chain genes alone did not enhance its secretion of 
heavy chain, indicating that heavy chain secretion is com-
plex [7]. In the absence of light chain, the heavy chain may 
fold improperly in the ER or Golgi apparatus. Increasing the 
efficiency of cell co-transfection is also difficult, with 
co-transfection of AAV vectors into cultured cells resulting 
in successful infection of only about 50% [14].  
We recently developed an alternative dual-vector strate-
gy to transfer the FVIII gene. Using protein trans-splicing, 
we found that the target cells expressed FVIII heavy and 
light chain, which were ligated to form intact FVIII protein 
by fused intein, a protein splicing element, yielding a prod-
uct similar to that of the FVIII transgene. The light chain in 
spliced FVIII protein has a cis-prompting effect on heavy 
chain secretion. The secreted heavy and light chains can 
also be spliced, suggesting that protein splicing is inde-
pendent of any cellular mechanism(s), and suggesting that it 
is not necessary for both chains to enter the same target cell 
[1,7]. The ability of protein splicing extracellularly is a 
unique advantage over non-protein splicing-based dual 
vector co-transgenic technology. However, protein 
trans-splicing occurs between the FVIII heavy and light 
chain polypeptides, so the efficiency of splicing determines 
the amounts of spliced FVIII protein and coagulation activ-
ity. Protein trans-splicing may be improved by enhancing 
the interactions of FVIII heavy and light chains. Mutation of 
Met662 in the A2 domain of the heavy chain and Asp1828 
in the A3 domain of light chain to Cys resulted in the for-
mation of a disulfide bond between these two Cys residues. 
This linkage between heavy and light chains did not affect 
FVIII activity while prolonging its half-life following 
thrombin activation. Coinjection of two vectors encoding 
the FVIII heavy and light chain with Cys mutations into 
mice through the portal vein increased plasma coagulation 
activity, suggesting that the secretion of disulfide cross-
linked heterodimeric FVIII had increased [18]. Fusing in-
tein sequences to the FVIII heavy and light chains, fol-
lowed by dual-vector transfection into cultured cells, in-
creased the secretion of spliced FVIII protein and activity 
indicating that the inter-chain disulfide bond improved pro-
tein trans-splicing [5]. In this study, we co-injected vectors 
encoding intein-tagged and Cys-mutated FVIII heavy and 
light chains into the livers of mice via the portal vein. We 
found that the procoagulation activity of mouse plasma was 
markedly increased, indicating an increased secretion of 
spliced FVIII protein. The disulfide bond helps to join the 
heavy and light chains, making inter-peptide trans-splicing 
similar to intra-peptide cis-splicing resulting in increased 
FVIII protein and plasma coagulation activity following 
secretion. The increased secretion into plasma of heavy 
chain peptide decreases its intracellular deposition, reducing 
cell pressure and reducing the amount of nonfunctional, 
unmatched plasma light chain polypeptide. The increased 
amounts of heavy and light chain peptides in plasma con-
tribute to coagulation activity, indicating that these two 
chains are present as heterodimeric FVIII derived from 
spliced FVIII. As a result, chain imbalance is also alleviated. 
Because the spliced protein is similar to that expressed by 
the single vector FVIII transgene, ligation by protein splic-
ing may increase the secretion of glycosylation modified 
heavy chain, thus enhancing coagulation activity [19].  
These findings indicate that protein trans-splicing-based 
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dual-vector approach produces a spliced FVIII identical in 
structure to physiologically synthesized cellular FVIII and 
with similar plasma coagulation activity. Thus, transgene 
efficacy may be increased by enhancing protein trans- 
splicing by the introduction of inter-chain disulfide bonds. 
In addition, although the A and C domains of FVIII and 
coagulation factor V (FV) have 40% sequence homology, 
the secretion of FVIII is less efficient than that of FV, indi-
cating that FVIII is present in a particular configuration and 
that its cellular trafficking and processing are complex 
[16,20]. Our results indicate the need for methods to im-
prove the secretion of spliced FVIII and coagulation activity, 
based on methods that include point mutations and glyco-
sylation.  
As a novel biotechnology, protein trans-splicing has 
been used widely in protein research [21]. Its applications in 
gene therapy, via the dual-vector transfer of disease-causing 
large genes, require further exploration.  
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